Table 1.

Baseline characteristics of included studies

Author	Year	N	Sex(Male/Female)	Age	Disease status	Surgery	N in IMRT	N in 3D-CRT (Gy)	Dose of IMRT (Gy)	Dose of 3D-CRT	Fraction of IMRT	Fraction of 3D-CRT	Chemotherapy	Type	Stage (AJCC)
Xin Wang [22]	2016	100	82/28	55 (23–73)	stage IB-IIIC gastric cancer	curative resection with D2 lymph node dissection	42	68	50.4	50.4	28	28	5-FU+ CDDP	RCT	IB-IIIC
A. Yuriko Minn [29]	2010	57	38/19	58 (29–83)	gastric or gastroesophageal junction cancer	Esophagogastrectomy, total or subtotal gastrectomy	31	26	45	45	25	25	5-FU+ CDDP	RS	I-III
Gene-Fu F. Liu [26]	2014	24	18/6	56–64	stage IB-IIIB gastric cancer	Esophagogastrectomy, total or subtotal gastrectomy	12	12	50.4	45	25	25	5-FU	RS	IB-IIIC
Boda-Heggemann J [12]	2009	60	37/23	35–75	gastric or gastroesophageal junction cancer	D2 resection	33	27	45	45	25	25	5-FU+ CDDP	RS	I-IV
Boda-Heggemann J [34]	2013	65	38/27	35–76	gastric or gastroesophageal junction cancer	total or subtotal gastrectomy	38	27	45	45	25	25	5-FU+ CDDP	RS	I-IV
Chopra S [23]	2015	51	35/16	54 (25–74)	gastric or, proximal gastric and gastro-esophageal junction cancer	total or subtotal gastrectomy	26	25	45	45	25	25	Capecitabine	RS	I-III
Goody, R. B. [35]	2016	55	30/25	54 (28–77)	completely resected gastric cancer	total or subtotal gastrectomy	NA	NA	45	45	25	25	cisplatin	PS	I-III
Fang, L. [25]	2015	75	54/21	47 (31–58)	stage III-IV gastric cancer	curative resection	25	25	45	45	NA	NA	None	RCT	III-IV
Deng, Q. H. [36]	2011	29	23/6	55 (29–72)	stage III-IV gastric cancer	total or subtotal gastrectomy	29	29	45	45	25	25	None	RS	III-IV (UICC)

Abbreviation: N number, IMRT intensity modulated radiation therapy, 3D-CRT three-dimensional conformal radiation treatment, RCT randomized controlled trial, 5-Fu 5-fluorouracil, NA not available, RS retrospective study, PS prospective study, AJCC American Joint Committee on Cancer, UICC UnionInternationale Against Cancer